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Meta-analysis and meta-regression of omega-3
polyunsaturated fatty acid supplementation for major
depressive disorder
RJT Mocking1, I Harmsen1, J Assies1, MWJ Koeter1, HG Ruhé1,2,5 and AH Schene3,4,5
Omega-3 polyunsaturated fatty acid (PUFA) supplementation has been proposed as (adjuvant) treatment for major depressive
disorder (MDD). In the present meta-analysis, we pooled randomized placebo-controlled trials assessing the effects of
omega-3 PUFA supplementation on depressive symptoms in MDD. Moreover, we performed meta-regression to test whether
supplementation effects depended on eicosapentaenoic acid (EPA) or docosahexaenoic acid dose, their ratio, study duration,
participants’ age, percentage antidepressant users, baseline MDD symptom severity, publication year and study quality. To limit
heterogeneity, we only included studies in adult patients with MDD assessed using standardized clinical interviews, and excluded
studies that speciﬁcally studied perinatal/perimenopausal or comorbid MDD. Our PubMED/EMBASE search resulted in 1955 articles,
from which we included 13 studies providing 1233 participants. After taking potential publication bias into account, meta-analysis
showed an overall beneﬁcial effect of omega-3 PUFAs on depressive symptoms in MDD (standardized mean difference = 0.398
(0.114–0.682), P= 0.006, random-effects model). As an explanation for signiﬁcant heterogeneity (I2 = 73.36, Po0.001),
meta-regression showed that higher EPA dose (β= 0.00037 (0.00009–0.00065), P= 0.009), higher percentage antidepressant users
(β= 0.0058 (0.00017–0.01144), P= 0.044) and earlier publication year (β=− 0.0735 (−0.143 to 0.004), P= 0.04) were signiﬁcantly
associated with better outcome for PUFA supplementation. Additional sensitivity analyses were performed. In conclusion, present
meta-analysis suggested a beneﬁcial overall effect of omega-3 PUFA supplementation in MDD patients, especially for higher doses
of EPA and in participants taking antidepressants. Future precision medicine trials should establish whether possible interactions
between EPA and antidepressants could provide targets to improve antidepressant response and its prediction. Furthermore,
potential long-term biochemical side effects of high-dosed add-on EPA supplementation should be carefully monitored.
Translational Psychiatry (2016) 6, e756; doi:10.1038/tp.2016.29; published online 15 March 2016
INTRODUCTION
Omega-3 polyunsaturated fatty acids (PUFAs) have been proposed
as a treatment for major depressive disorder (MDD). Over the last
decade, several meta-analyses have been performed, which
suggested variable degrees of beneﬁcial effects of omega-3
PUFAs for MDD, but made critical remarks regarding the quality of
the evidence and possible publication bias.1–6 These meta-
analyses evoked academic correspondence, discussing the used
inclusion criteria and selection of outcome measures.7,8 In brief,
this correspondence suggested beneﬁcial effects (1) if a higher
ratio of omega-3 PUFA eicosapentaenoic acid (EPA) to docosahex-
aenoic acid (DHA) was being supplemented7 and (2) only in
patients with actual MDD as opposed to subjects with merely
depressive symptoms.8
Of these meta-analyses, only the three most recent meta-
analyses covered the research performed over the last 5 years: (1)
Grosso et al.9 included randomized controlled trials (RCTs)
published up to August 2013, and concluded that omega-3
PUFAs were effective in depressive patients with or without an
MDD diagnosis; (2) Yang et al.10 pooled RCTs published up to
March 2015 on the effect of the combination of EPA and DHA on
depression in women and observed a beneﬁcial effect; and (3)
Appleton et al.4 performed a Cochrane meta-analysis of RCTs
published up to May 2015, concluding that there is a small-to-
modest, non-clinically beneﬁcial effect of omega-3 PUFAs.
Importantly, these meta-analyses seem to have several issues of
interest. First, they did not correct for potential publication bias,
for example, by using the trim-and-ﬁll method.11 Second, Grosso
et al. included two comparisons of the study of Jazayeri et al.12
This study had three arms using a double-dummy technique (EPA
+placebo vs EPA+ﬂuoxetine vs ﬂuoxetine+placebo). Although
other meta-analyses only included the ﬂuoxetine+EPA vs ﬂuox-
etine+placebo comparison (that is, EPA vs placebo in an add-on
design), Grosso et al. additionally included the EPA+placebo vs
ﬂuoxetine+placebo comparison (that is, EPA vs ﬂuoxetine during
additional placebo treatment). Thereby, Grosso et al. not only
compared EPA vs placebo, but additionally included a comparison
of EPA vs active antidepressant medication, potentially reducing
the overall effect size. Third, Grosso et al. and Yang et al. included
three articles that all seem to report on the same RCT,13–15 that
is, (partial) duplicate publication which distorts pooled-effect
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estimates. Fourth, Grosso et al. and Appleton et al. missed
potentially important evidence by not including all RCTs on MDD
patients in their analysis (for example, Lesperance et al.16 in Grosso
et al.; and Mozaffari-Khosravi et al.17 in Appleton et al.). Although
the study of Mozaffari-Khosravi et al. included mild-to-moderate
MDD patients, all patients fulﬁlled MDD criteria, baseline severity
was comparable to other included studies and other included
studies (for example, Lucas et al.18) also used an upper limit for
MDD severity. Fifth, all three meta-analyses only used post-
intervention effect size data, while repeated measures are
available, which may improve effect size estimation precision.
Sixth, by including RCTs that not only included MDD patients but
also patients with dysthymia,13,14 all three meta-analyses did not
speciﬁcally focus on MDD only. In addition, Appleton et al.
included the trial by Peet and Horrobin19 that did not use MDD
diagnosis as an inclusion criterion, but rather a cutoff score on a
depression symptom questionnaire. Moreover, Appleton et al. and
Grosso et al. also included trials on subjects with MDD secondary
to neurological or other somatic disorders (for example, Da Silva
et al.),20 which may increase heterogeneity due to different
underlying pathophysiology.
Therefore, our study aims at continuing the academic debate by
performing a revised updated meta-analysis on the effectiveness
of omega-3 PUFAs for the treatment of MDD taking into account
the above issues of concern. In addition, we performed meta-
regression analyses to explain expected heterogeneity, by testing
the effects of EPA and DHA dose and their ratio, study duration,
participants’ age, percentage antidepressant users, baseline MDD
symptom severity, publication year and study quality.
MATERIALS AND METHODS
Search strategy
We performed a search in the Medline and Embase databases (from
inception up to 8 December 2015). We used a search strategy combining
terms regarding MDD and fatty acid supplementation using Boolean
operators (See Supplementary Methods). We additionally searched
references of selected studies and earlier meta-analyses for potential
studies.1,4,9
Study selection
Two independent reviewers (RJTM and IH/JA) screened the identiﬁed
articles for their relevance by title and abstract, and—if necessary—the full
text. In case of disagreement between reviewers, inclusion could be
conclusively determined by discussion in all the cases. A priori criteria for
inclusion of studies were: (1) design was a randomized placebo-controlled
trial; (2) inclusion of adult patients with MDD according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM) as assessed by a
standardized clinical interview. We excluded studies that (1) speciﬁcally
studied perinatal or perimenopausal MDD or (2) MDD secondary to other
neuropsychiatric disorders.
With these in- and exclusion criteria, we aimed to test the effect
of omega-3 fatty acid supplementation on depressive symptoms
speciﬁcally in MDD, as opposed to depressive symptoms in the general
population (including subclinical depression). Because previous
meta-analyses included clinically more heterogeneous populations
which theoretically may preclude meta-analysis, we aimed to prevent
inclusion of trials where supplementation of omega-3 fatty acids could
improve an underlying somatic or (neuro)psychiatric disorder, with a
secondary effect on the depression scores. In addition, by excluding
speciﬁc subgroups like perinatal or perimenopausal MDD, with a
potentially different pathophysiology, we aimed to further minimize
heterogeneity among included studies. Because of the widespread
comorbidity between MDD and cardiovascular disease, we did not exclude
studies that speciﬁcally studied MDD with comorbid cardiovascular disease
or diabetes.21 Nevertheless, we performed sensitivity analyses without the
studies that speciﬁcally studied MDD with comorbid cardiovascular disease
or diabetes.22,23
Critical appraisal
We assessed the quality of the studies that were selected with the in- and
exclusion criteria above using the Jadad scale for reporting RCTs.24
Data extraction
Two independent reviewers (RJTM and IH) extracted the data into
speciﬁcally designed spreadsheets. We collected the data on descriptives,
methods and outcomes. Possible disagreements were resolved by
discussion with a third independent reviewer where necessary (JA).
We used the primary outcome measure reported by the study. We used
the unadjusted intention-to-treat repeated-measures statistics where
available. If multiple primary outcomes were reported, we used the
Hamilton Depression Rating Scale (HDRS).25 If unavailable, we used
another clinician-rated outcome. If unavailable, we used a self-rated
depression scale. We performed sensitivity analyses using unpublished
additional data derived from the authors where available.4,12,26,27
Statistical analysis
We performed the statistical analyses with Comprehensive Meta-Analysis
version 2. We used standardized mean differences as the summary statistic
for meta-analysis. We assessed heterogeneity by calculating the I2
statistic.11 Given the expected heterogeneity, we a priori used a random-
effects model.11 We performed the sensitivity analyses using ﬁxed-effects
models because they are considered to be less vulnerable for publication
bias. We assessed publication bias by plotting a funnel plot, and reporting
the classic and Orwin’s fail-safe N, Begg and Mazumdar rank correlation
and Egger’s regression intercept.11 Finally, we adjusted the values using
the Duval and Tweedie’s trim-and-ﬁll method.
We performed meta-regression using the method of moments compu-
tational option.11 We a priori planned to test the univariate effects of EPA
and DHA dose, study duration, participants’ age, percentage antidepres-
sant users, baseline MDD severity, publication year and study quality, on
the effect size of trials. To compare EPA- and DHA-dose effects for studies
where multiple subgroups were available, we regarded these subgroups as
independent, assuming independence where necessary.11 For baseline
severity, we converted scores to the 17-item Hamilton Depression Rating
Scales using available conversion tables where needed.28,29
RESULTS
Selection of studies
The search strategy resulted in 1955 articles for consideration in
the present meta-analysis. The studies were excluded for several
reasons, including not applying a randomized placebo-controlled
trial design, no inclusion of subjects with MDD as ascertained by a
structured clinical interview,30–33 or speciﬁcally including patients
with perinatal or perimenopausal MDD, or MDD secondary to
other neuropsychiatric disorders20,34 (Supplementary Figure S1).
After applying the in- and exclusion criteria, we included 15
studies,12,16–18,22,23,26,35–42 including a total of 1253 MDD subjects.
Study-characteristics are provided in Supplementary Table 1. Of
these 15 studies, 1 small preliminary study reports unpublished
data (Coryell et al., related to Fiedorowicz et al.42), and 1 small
study has a considerable drop-out rate (450%).41 Given the
relatively preliminary nature of these two studies, we included
them only in separate sensitivity analyses.
Meta-analysis
The meta-analysis on 13 RCTs in 1233 MDD subjects showed an
overall beneﬁcial effect of omega-3 PUFAs on depressive
symptoms in MDD (standardized mean difference = 0.398
(0.114–0.682), P= 0.006, random-effects model, Figure 1). For the
sensitivity analyses, see Supplementary Results.
Publication bias
The funnel plot for all the available data is shown in
Supplementary Figure 2. The classic fail-safe N was 95, Orwin’s
fail-safe N was 19 with criterion for a ‘trivial’ standardized
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difference in means as 0.1 and mean standardized difference in
means in missing studies as 0. This implied that at least 19 studies
without any effect must have been left unpublished to reduce the
overall effect to a trivial effect. Regarding the Begg and Mazumbar
rank-correlation test, Kendall’s taus with and without continuity
correction were 0.21 (P2-sided = 0.28), and 0.22 (P2-sided = 0.26),
respectively, indicative of no publication bias. Egger’s regression
intercept was 1.13 (95% conﬁdence interval: − 0.63 to 2.91; P2-
sided = 0.19), also suggesting no signiﬁcant publication bias. Duval
and Tweedie’s trim-and-ﬁll method used the random-effects
model looking for missing studies to the left of the mean, that
is, less positive effect of supplementation, and showed that no
studies needed to be trimmed. See Supplementary Results for
sensitivity analyses.
Meta-regression
Method-of-moments meta-regressions were performed to explain
signiﬁcant heterogeneity (Q= 45.04, Po0.001, I2 = 73.36). Higher
EPA dose (β= 0.00037 (0.00009–0.00065), P= 0.009), higher
percentage antidepressant users (β= 0.0058 (0.00017–0.01144),
P= 0.044) and earlier publication year (β=− 0.0735 (−0.143 to
− 0.004), P= 0.04) were signiﬁcantly associated with a better
outcome for PUFA administration, whereas DHA dose (β= 0.00015
(−0.00029 to 0.00059), P= 0.498), EPA/(EPA+DHA) ratio (β= 0.0044
(−0.0034 to 0.012), P= 0.272), study duration (β=− 0.012 (−0.026
to 0.002), P= 0.086), baseline severity (β=− 0.00023 (−0.14 to
0.14), P= 0.997), age (β=− 0.036 (−0.075 to 0.002), P= 0.06) and
Jadad score (β=− 0.0791 (−0.327 to 0.169), P= 0.531) were not
signiﬁcantly associated. See Supplementary Results for the
sensitivity analyses.
DISCUSSION
Our revised updated meta-analysis adds nuance to the continuing
debate on the effect of omega-3 PUFA supplementation on
depressive symptoms in MDD. By addressing several issues as
noted in the introduction, the present meta-analysis studied
effects of omega-3 PUFA supplementation in all available
evidence in a speciﬁc relatively homogeneous group of MDD
subjects. Overall, with an standardized mean difference of 0.398
present meta-analysis shows a beneﬁcial effect of omega-3 PUFAs
that is comparable to effects reported in meta-analyses of
antidepressants.43 Of note, this effect seemed larger in studies
(1) supplementing higher doses of EPA and (2) performed in
patients using antidepressants (augmentation/add-on), while it
was independent of baseline depression severity or EPA/(EPA
+DHA) ratio. However, more recent trials had smaller effect sizes,
independent of trial quality.
By including a relatively homogeneous group of patients with
MDD according to DSM criteria as assessed using a standardized
clinical interview, we aimed to enhance internal validity and
generalizability of the present meta-analysis. Nevertheless, the
included MDD patients still form a heterogeneous group including
both subjects that will beneﬁt from omega-3 PUFA supplementa-
tion and those that experience no or even negative effects.21
Several other unreported factors may inﬂuence the response to
omega-3 PUFA, which could not be tested in the present meta-
analysis and meta-regression, for example, measurements of
inﬂammation or nutrigenetics.44–47
Nevertheless, we were able to test sample and trial-related
factors that may inﬂuence omega-3 PUFA response. In the present
meta-analysis, response was independent of baseline MDD
symptom severity. This may be because we included a relatively
homogeneous sample of MDD patients in comparison with earlier
meta-analyses that also included subjects with depressive
symptoms.1 In contrast to the lack of effect of baseline severity,
we noticed that the effects of supplementation seemed larger in
patients being treated with antidepressants compared with
patients not being concurrently treated with antidepressants. Of
note, MDD baseline severity was not associated with percentage
antidepressant use across trials (P= 0.778). Therefore, this larger
effect in trials where patients were being treated with antide-
pressants suggests an interaction between antidepressant use and
omega-3 PUFAs at the biological level, for example, due to PUFAs’
modulating effect on neuronal membrane–antidepressant inter-
actions or on inﬂammatory pathways.21,45,48,49 In addition, omega-
3 PUFAs may interfere with serotonergic neurotransmission,50 or
antidepressant transport across the blood–brain barrier by
inﬂuencing p-glycoprotein.51 It could be highly clinically relevant
to follow up on this ﬁnding that omega-3 PUFAs seem to have
more effect in studies where participants use antidepressants,
by further investigating the interaction between omega-3 PUFAs
Study name Comparison Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Nemets 2002 Blank 1.876 0.537 0.288 0.824 2.928 3.496 0.000
Marangell 2003 Blank 0.416 0.342 0.117 -0.254 1.086 1.216 0.224
Su 2003 Blank 2.067 0.530 0.280 1.029 3.105 3.903 0.000
Grenyer 2007 Blank -0.091 0.220 0.048 -0.521 0.340 -0.412 0.680
Jazayeri 2008 Blank 1.084 0.379 0.143 0.342 1.826 2.863 0.004
Carney 2009 Blank 0.212 0.182 0.033 -0.144 0.568 1.168 0.243
Lucas 2009 Blank -0.663 0.383 0.147 -1.415 0.088 -1.730 0.084
Mischoulon 2009 Blank 0.543 0.345 0.119 -0.134 1.220 1.572 0.116
Bot 2010 Blank -0.521 0.415 0.172 -1.335 0.292 -1.256 0.209
Lespérance 2011 Blank 0.152 0.096 0.009 -0.036 0.341 1.581 0.114
Gertsik 2012 Blank 0.860 0.332 0.110 0.209 1.511 2.590 0.010
Mozaffari-Khosravi 2012 Combined 0.629 0.324 0.105 -0.006 1.265 1.941 0.052
Mischoulon 2015 Combined 0.065 0.184 0.034 -0.296 0.426 0.353 0.724
0.398 0.145 0.021 0.114 0.682 2.746 0.006
-2.00 -1.00 0.00 1.00 2.00
Favors Placebo Favors Omega-3
Figure 1. Forest plot of the meta-analysis on the effect of omega-3 fatty acid supplementation on depressive symptoms in major depressive
disorder. For the comparison column, ‘blank’ means that there was only one comparison in the study, ‘combined’ means that different
comparisons were combined for an overall study estimate. Studies are sorted by publication year.
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and antidepressants from (integrated) biological and clinical
perspectives.
The present meta-regression ﬁnding that higher EPA dose was
associated with better response, nuances an earlier meta-analysis
that observed signiﬁcant effects after applying a dichotomous
cutoff at 60% EPA content.7 First, although it remained relatively
unclear how this previous cutoff was derived, our regression
model suggested a linear relationship in all the available data
without using an artiﬁcial cutoff. In addition, the present meta-
analysis also showed that EPA/(EPA+DHA) ratio had no signiﬁcant
effect, nor had DHA dose. Altogether, this suggests that it is not
the ratio of EPA vs DHA that is important, but rather the higher
EPA dose. Although hypothesized, it does not seem that DHA
counteracts the effects of EPA (for example, by competition for
target proteins or membrane incorporation);6,52,53 DHA simply has
no detectable pooled effect on the MDD symptoms. Nevertheless,
it remains surprising that EPA seems to be responsible for the
beneﬁcial effects of omega-3 PUFA supplementation while DHA
concentrations appear to differ more between patients and
controls.54 In addition, the regression effect of EPA dose on RCT
outcome depended to some extent on one trial that supplemen-
ted the highest EPA concentration.26 On the basis of these
ﬁndings, it could be argued that the beneﬁcial effects of omega-3
PUFA supplementation are not because supplementation corrects
a membrane DHA ‘deﬁcit’, but rather due to the anti-inﬂammatory
characteristics of EPA’s oxidation products.21 Future mechanistic
studies in a more continuous dose range should follow up on
these ﬁndings.
However, these oxidation products may not have positive
effects only. Relatively little is known about the precise role and
effect of the great diversity of PUFA oxidation products. Although
adverse events reported during the studies were usually mild and
gastrointestinal in nature (for example, belching, constipation,
ﬁshy aftertaste), exposure to PUFA oxidation products with
unknown effects may pose unknown risks in the long
term.21,47,55 It may therefore be advisable to measure these
oxidation products during future studies with a longer follow-up
to obtain more insight in their potential toxicity. In addition, ﬁshy
aftertaste may result in unblinding, potentially distorting effect
sizes.4,56
The ﬁnding that more recent studies showed smaller effects
remains puzzling. It seems independent from study quality, as we
observed no association between study effect size and study
quality operationalized as Jadad score. It may be that differences
in background diet over time contributed to smaller effects of
additional omega-3 PUFA supplementation. For example, even
though studies usually excluded participants that used omega-3
PUFA supplements on their own initiative at baseline, it may be
that participants started using omega-3 PUFA supplements during
the study owing to their increasing popularity, thereby diminish-
ing outcome differences in more recent trials. Unfortunately, not
enough trials provided uniform data regarding baseline omega-3
PUFA status or intake to formally test this,57 which would be
interesting in future research.
Limitations and strengths
Despite several strengths of this meta-analysis, some limitations
should be noted. First, the present meta-analysis has not been
performed on patient level data. It would be interesting to conﬁrm
these ﬁndings on a patient level. Moreover, this may also lead to
additional predictors of supplementation outcome, giving rise to
extra targets for future precision medicine studies. We hope
researchers will be motivated to share and pool available data in
the future. Furthermore, while the present meta-analysis had
enough power to detect small-to-medium effect sizes, smaller
regression effects may have been lost as a result of the smaller
number of studies due to the speciﬁc in- and exclusion criteria. In
addition, several concerns regarding the quality of the available
evidence could be made,4 like in most meta-analyses. Further
high-quality evidence to support a beneﬁcial effect of EPA in
(antidepressant using) MDD patients could lead to more precise
estimates of overall effect size. Finally, to maintain power for the
meta-regression regarding the effect of percentage antidepres-
sant users on supplementation outcome, we pooled all concurrent
antidepressant classes together, while the effects may differ per
class. It would be interesting to further test this in future studies
including users of different antidepressants.
Nonetheless, the present study/analyses focused on studies that
speciﬁcally included patients with MDD according to diagnostic
criteria as ascertained with a structured clinical interview. We thus
limited clinical heterogeneity while still maintaining a substantial
overall sample size. As a second strength, by performing extensive
nuanced a priori planned publication bias analyses and meta-
regression analyses, we revealed new evidence for (1) an effect of
EPA dose as opposed to EPA to DHA ratio and (2) an interaction
between omega-3 PUFAs and antidepressants, both of which may
be highly relevant for clinical practice.
Conclusion
In conclusion, the present meta-analysis observed a beneﬁcial
overall effect of omega-3 PUFA supplementation in patients with
MDD according to diagnostic criteria, which seemed larger in
studies that supplemented higher doses of EPA and included
patients taking antidepressants. Future precision/personalized
medicine trials should establish whether possible interactions
between EPA and antidepressants could provide targets
to improve antidepressant response and its prediction.48
Nevertheless, potential long-term biochemical side effects of
high-dosed add-on EPA supplementation should be carefully
monitored.21
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